GlassScriptPhysician profile
Thomas F Gajewski
NPI 1194888610
$76,709.66
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $3,143 · 2021: $23K · 2022: $4,856 · 2023: $23K · 2024: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $10K · Consulting Fee: $9,448 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Education: $850 · Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,236.93 |
| Consulting Fee | $9,447.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Education | $850.00 |
| Food and Beverage | $825.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21,254.47 | 2019-2024 | |
| Abbvie INC. | $17,617.96 | 2021-2023 | |
| Pfizer INC. | $10,000.00 | 2021 | |
| Roche Molecular Systems, INC. | $5,884.29 | 2021-2023 | |
| Incyte Corporation | $3,633.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $3,549.28 | 2019-2023 | |
| Gilead Sciences, INC. | $3,400.00 | 2021 | |
| Ventana Medical Systems, INC. | $2,852.63 | 2019 | |
| Janssen Global Services, LLC | $2,480.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $1,828.57 | 2019 | |
| Seagen INC. | $1,650.00 | 2021 | |
| Astellas Pharma INC | $1,550.00 | 2021 | |
| Amgen INC. | $750.00 | 2019 | |
| Bristol Myers Squibb Company | $143.10 | 2020 | |
| Medtronic, INC. | $116.36 | 2024 | Signia |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gajewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.